

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

**APPOINTMENT OF CHIEF STRATEGY OFFICER
AND
RESIGNATION OF JOINT COMPANY SECRETARY**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes to the Company’s senior management.

Appointment of Chief Strategy Officer

The Board is pleased to announce that Dr. Xiaochang Dai (戴曉暢) (“**Dr. Dai**”) has been appointed as the Chief Strategy Officer of the Group, re-designated from the position of Scientific and Strategic Director by the Board with effect from August 30, 2023, due to changes in his functions and responsibilities within the Group.

The biographical details of Dr. Dai are set out as follows:

Dr. Dai, aged 60, is an executive Director and the Chief Strategy Officer of the Group. Dr. Dai participates in the formulation of the general corporate business plans, strategies and major decisions of the Company through the Board. Dr. Dai is a member of the remuneration committee of the Board (the “**Remuneration Committee**”). He is also a director of certain subsidiaries of the Company.

Dr. Dai currently serves as a professor at School of Chemical Science and Engineering, Yunnan University since 2000, the executive director of Value Measure Investments Limited since January 2011 and the executive director of Trinity Power Limited since March 2012, respectively. Dr. Dai also serves as a director of Shenzhen Yunda Technology Industry Co., Ltd. (深圳市雲大科技產業有限公司) since August 2001.

Prior to joining the Group, Dr. Dai served as the executive director, director of scientific advisory committee, director of postdoctoral workstation, chief scientist at Yunda Technology Co., Ltd. (雲大科技股份有限公司), a company used to be listed on Shanghai Stock Exchange (stock code: 600181) and delisted since June 1, 2007, from January 2000 to December 2001, the chairman and general manager of Dalian High-tech Biopharmaceutical Co., Ltd. (大連高新生物製藥有限公司) in 2001, the chairman of Yunnan Walvax Biopharmaceutical Co., Ltd. (雲南沃森生物製藥有限公司), the predecessor of Walvax Biotechnology Co., Ltd. (雲南沃森生物技術股份有限公司), a company listed on Shenzhen Stock Exchange (stock code: 300142) from 2002 to 2004, the managing director of Kunming Baker Norton Pharmaceutical Co., Ltd. (昆明貝克諾頓製藥有限公司) in 2005, and the president of Kunyao Group Co., Ltd. (昆藥集團股份有限公司), a company listed on Shanghai Stock Exchange (stock code: 600422), from September 2015 to December 2017.

Dr. Dai obtained a bachelor's degree in chemistry in School of Chemistry, Yunnan Normal University in the PRC in July 1983, a master's degree in biochemistry in Shanghai Institute of Biochemistry, Chinese Academy of Sciences in the PRC in July 1988, and a doctoral degree in chemistry from The Scripps Research Institute in San Diego, California, U.S. in September 1998, respectively. He also conducted postdoctoral research in the laboratory of John N. Ableson, Division of Biology and Biological Engineering, California Institute of Technology in the U.S. from November 1998 to December 1999.

The Board considered and accepted the recommendation from the nomination committee of the Board to the appointment of Dr. Dai as Chief Strategy Officer, after reviewing his academic qualifications, working experience and contributions to the Group.

As at the date of this announcement, Dr. Dai was deemed to be interested in an aggregate of 8,545,007 shares of the Company (the “**Shares**”) and underlying Shares, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Dai is entitled to an annual emolument of US\$277,650 which is determined by the Board with reference to his background, qualifications, experience, level of responsibilities undertaken with the Group and prevailing market conditions. The emolument of Dr. Dai will be subject to annual review by the Remuneration Committee and the Board.

Save as disclosed above, as at the date of this announcement, Dr. Dai confirmed that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) he does not hold any other position with the Company or subsidiaries of the Company; (iii) he does not have any other major appointments and

professional qualifications; (iv) he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (v) he does not hold any other interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any other information relating to the appointment of Dr. Dai as Chief Strategy Officer that is required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and there are no other matters that need to be brought to the attention of the shareholders of the Company.

Resignation of Joint Company Secretary

The Board hereby announces that the Board has received a letter of resignation from Ms. Yun Zhang (*alias* Monica Zhang) (“**Ms. Zhang**”) to resign as a joint company secretary of the Company with effect from August 31, 2023. Ms. Zhang has confirmed that she had no disagreement with the Board and there were no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or the Hong Kong Stock Exchange.

Following the resignation of Ms. Zhang, the other joint company secretary of the Company, Mr. Leung Ting Cheung, who possesses the qualifications and experience of company secretary as required under Rule 3.28 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, will remain in office and act as the sole company secretary of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Zhang for her valuable contribution to the Company during her tenure of office as a joint company secretary of the Company.

By order of the Board
Sirnaomics Ltd.
Yang (Patrick) Lu
Chairman and Executive Director

Hong Kong, August 31, 2023

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Xiaochang Dai, Dr. Michael V. Molyneaux and Dr. David Mark Evans as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Mr. Fengmao Hua, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.